Macrophage gene expression and foam cell formation are regulated by plasminogen

Circulation

Volumn 127, Issue 11, 2013, Pages 1209-1218

  Das, Riku ^a   Ganapathy, Swetha ^a   Mahabeleshwar, Ganapati H ^b   Drumm, Carla ^a   Febbraio, Maria ^a   Jain, Mukesh K ^b   Plow, Edward F ^a  

^a Department of Molecular Cardiology ^*  (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Cholesterol; Plasminogen

Indexed keywords

CD36 ANTIGEN; CHOLESTEROL; LEUKOTRIENE B4; OXIDIZED LOW DENSITY LIPOPROTEIN; PLASMIN; PLASMINOGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL SURFACE; CHOLESTEROL METABOLISM; CONTROLLED STUDY; EX VIVO STUDY; EXPOSURE; FEMALE; FOAM CELL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; INTRACELLULAR SIGNALING; LIPID STORAGE; MACROPHAGE; MALE; METABOLIC REGULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN BINDING;

ANIMALS; ANTIGENS, CD36; CELL DIFFERENTIATION; CHOLESTEROL; FOAM CELLS; GENE EXPRESSION REGULATION; LEUKOTRIENE B4; LIPOPROTEINS, LDL; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, ANIMAL; PLASMINOGEN; SIGNAL TRANSDUCTION;

EID: 84875205333     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.001214     Document Type: Article

References (38)

1. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104:503-516.
2. Shashkin P, Dragulev B, Ley K. Macrophage differentiation to foam cells. Curr Pharm Des. 2005;11:3061-3072.
3. Plow EF, Herren T, Redlitz A, Miles LA, Hoover-Plow JL. The cell biology of the plasminogen system. FASEB J. 1995;9:939-945.
4. Ploplis VA, Carmeliet P, Vazirzadeh S, Van Vlaenderen I, Moons L, Plow EF, Collen D. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice. Circulation. 1995;92:2585-2593.
5. Miles LA, Hawley SB, Baik N, Andronicos NM, Castellino FJ, Parmer RJ. Plasminogen receptors: the sine qua non of cell surface plasminogen activation. Front Biosci. 2005;10:1754-1762.
6. Plow EF, Hoover-Plow J. The functions of plasminogen in cardiovascular disease. Trends Cardiovasc Med. 2004;14:180-186.
7. Syrovets T, Simmet T. Novel aspects and new roles for the serine protease plasmin. Cell Mol Life Sci. 2004;61:873-885.
8. Laumonnier Y, Syrovets T, Burysek L, Simmet T. Identification of the annexin A2 heterotetramer as a receptor for the plasmin-induced signaling in human peripheral monocytes. Blood. 2006;107:3342-3349.
9. Weide I, Römisch J, Simmet T. Contact activation triggers stimulation of the monocyte 5-lipoxygenase pathway via plasmin. Blood. 1994;83:1941-1951.
10. Poeckel D, Funk CD. The 5-lipoxygenase/leukotriene pathway in preclinical models of cardiovascular disease. Cardiovasc Res. 2010;86:243-253.
11. Aiello RJ, Bourassa PA, Lindsey S, Weng W, Freeman A, Showell HJ. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol. 2002;22:443-449.
12. Subbarao K, Jala VR, Mathis S, Suttles J, Zacharias W, Ahamed J, Ali H, Tseng MT, Haribabu B. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol. 2004;24:369-375.
13. Rajecki M, Pajunen P, Jousilahti P, Rasi V, Vahtera E, Salomaa V. Hemostatic factors as predictors of stroke and cardiovascular diseases: the FINRISK '92 Hemostasis Study. Blood Coagul Fibrinolysis. 2005;16:119-124.
14. Folsom AR, Aleksic N, Park E, Salomaa V, Juneja H, Wu KK. Prospective study of fibrinolytic factors and incident coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Arterioscler Thromb Vasc Biol. 2001;21:611-617.
15. Sakkinen PA, Cushman M, Psaty BM, Rodriguez B, Boineau R, Kuller LH, Tracy RP. Relationship of plasmin generation to cardiovascular disease risk factors in elderly men and women. Arterioscler Thromb Vasc Biol. 1999;19:499-504.
16. Morange PE, Bickel C, Nicaud V, Schnabel R, Rupprecht HJ, Peetz D, Lackner KJ, Cambien F, Blankenberg S, Tiret L; AtheroGene Investigators. Haemostatic factors and the risk of cardiovascular death in patients with coronary artery disease: the AtheroGene study. Arterioscler Thromb Vasc Biol. 2006;26:2793-2799.
17. Koenig W, Rothenbacher D, Hoffmeister A, Griesshammer M, Brenner H. Plasma fibrin D-dimer levels and risk of stable coronary artery disease: results of a large case-control study. Arterioscler Thromb Vasc Biol. 2001;21:1701-1705.
18. Xiao Q, Danton MJ, Witte DP, Kowala MC, Valentine MT, Bugge TH, Degen JL. Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis. Proc Natl Acad Sci U S A. 1997;94:10335-10340.
19. Kremen M, Krishnan R, Emery I, Hu JH, Slezicki KI, Wu A, Qian K, Du L, Plawman A, Stempien-Otero A, Dichek DA. Plasminogen mediates the atherogenic effects of macrophage-expressed urokinase and accelerates atherosclerosis in apoE-knockout mice. Proc Natl Acad Sci U S A. 2008;105:17109-17114.
20. Iwaki T, Donahue DL, Sandoval-Cooper MJ, Castellino FJ, Ploplis VA. A plasminogen deficiency attenuates atherosclerosis as a result of altered lipoprotein processing [abstract]. Presented at: International Society on Thrombosis and Haemostasis XXII Congress; Boston, Massachusetts; July 11-16, 2009.
21. Iwaki T, Malinverno C, Smith D, Xu Z, Liang Z, Ploplis VA, Castellino FJ. The generation and characterization of mice expressing a plasmin-inactivating active site mutation. J Thromb Haemost. 2010;8:2341-2344.
22. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest. 2000;105:1049-1056.
23. Das R, Burke T, Plow EF. Histone H2B as a functionally important plasminogen receptor on macrophages. Blood. 2007;110:3763-3772.
24. Ploplis VA, French EL, Carmeliet P, Collen D, Plow EF. Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice. Blood. 1998;91:2005-2009.
25. Osterud B, Bjorklid E. Role of monocytes in atherogenesis. Physiol Rev. 2003;83:1069-1112.
26. Xie S, Lee YF, Kim E, Chen LM, Ni J, Fang LY, Liu S, Lin SJ, Abe J, Berk B, Ho FM, Chang C. TR4 nuclear receptor functions as a fatty acid sensor to modulate CD36 expression and foam cell formation. Proc Natl Acad Sci U S A. 2009;106:13353-13358.
27. Huh HY, Pearce SF, Yesner LM, Schindler JL, Silverstein RL. Regulated expression of CD36 during monocyte-to-macrophage differentiation: potential role of CD36 in foam cell formation. Blood. 1996;87:2020-2028.
28. Doi K, Hamasaki Y, Noiri E, Nosaka K, Suzuki T, Toda A, Shimizu T, Fujita T, Nakao A. Role of leukotriene B4 in accelerated hyperlipidaemic renal injury. Nephrology (Carlton). 2011;16:304-309.
29. López-Parra M, Titos E, Horrillo R, Ferré N, González-Périz A, Martínez-Clemente M, Planagumà A, Masferrer J, Arroyo V, Clària J. Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice. J Lipid Res. 2008;49:2513-2523.
30. Xu S, McKeever BM, Wisniewski D, Miller DK, Spencer RH, Chu L, Ujjainwalla F, Yamin TT, Evans JF, Becker JW, Ferguson AD. Expression, purification and crystallization of human 5-lipoxygenase-activating protein with leukotriene-biosynthesis inhibitors. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007;63(pt 12):1054-1057.
31. Park YM, R Kashyap S, A Major J, Silverstein RL. Insulin promotes macrophage foam cell formation: potential implications in diabetes-related atherosclerosis. Lab Invest. 2012;92:1171-1180.
32. Halvorsen B, Waehre T, Scholz H, Clausen OP, von der Thüsen JH, Müller F, Heimli H, Tonstad S, Hall C, Frøland SS, Biessen EA, Damås JK, Aukrust P. Interleukin-10 enhances the oxidized LDL-induced foam cell formation of macrophages by antiapoptotic mechanisms. J Lipid Res. 2005;46:211-219.
33. Selvarajan S, Lund LR, Takeuchi T, Craik CS, Werb Z. A plasma kallikrein-dependent plasminogen cascade required for adipocyte differentiation. Nat Cell Biol. 2001;3:267-275.
34. Hoover-Plow J, Ellis J, Yuen L. In vivo plasminogen deficiency reduces fat accumulation. Thromb Haemost. 2002;87:1011-1019.
35. Podrez EA, Febbraio M, Sheibani N, Schmitt D, Silverstein RL, Hajjar DP, Cohen PA, Frazier WA, Hoff HF, Hazen SL. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest. 2000;105: 1095-1108.
36. Werz O, Klemm J, Samuelsson B, Rådmark O. 5-Lipoxygenase is phosphorylated by p38 kinase-dependent MAPKAP kinases. Proc Natl Acad Sci U S A. 2000;97:5261-5266.
37. Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest. 2004;114:1564-1576.
38. Anderson HV, Cannon CP, Stone PH, Williams DO, McCabe CH, Knatterud GL, Thompson B, Willerson JT, Braunwald E. One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial: a randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol. 1995;26:1643-1650.